NRX Pharmaceuticals Files 8-K
Ticker: NRXPW · Form: 8-K · Filed: Apr 15, 2024 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Apr 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $0.0001, $4,852,909, $1.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
NRX Pharma filed a routine 8-K, no major news yet.
AI Summary
NRX Pharmaceuticals, Inc. filed an 8-K on April 15, 2024, reporting other events and financial statements. The company, formerly known as Big Rock Partners Acquisition Corp., is incorporated in Delaware and headquartered in Wilmington. This filing does not contain specific details on new events or financial figures beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates NRX Pharmaceuticals is meeting its regulatory reporting obligations. Investors should review the full filing for any specific disclosures that may impact the company's operations or financial standing.
Risk Assessment
Risk Level: low — This filing is a standard 8-K report and does not contain information that inherently increases risk.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- Big Rock Partners Acquisition Corp. (company) — Former company name
- Delaware (location) — State of incorporation
- Wilmington (location) — City of headquarters
- April 15, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for NRX Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of April 15, 2024.
When was NRX Pharmaceuticals, Inc. previously known by another name?
NRX Pharmaceuticals, Inc. was formerly known as Big Rock Partners Acquisition Corp., with a name change date of October 12, 2017.
In which state is NRX Pharmaceuticals, Inc. incorporated?
NRX Pharmaceuticals, Inc. is incorporated in Delaware.
What is the business address of NRX Pharmaceuticals, Inc.?
The business address of NRX Pharmaceuticals, Inc. is 1201 Orange Street, Suite 600, Wilmington, Delaware 19801.
What is the Commission File Number for NRX Pharmaceuticals, Inc.?
The Commission File Number for NRX Pharmaceuticals, Inc. is 001-38302.
Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-04-15 17:22:56
Key Financial Figures
- $0.001 — h registered Common Stock, par value $0.001 per share NRXP The Nasdaq Stock Mar
- $0.0001 — f the Company's common stock, par value $0.0001 per share (the "Common Stock") issuable
- $4,852,909 — wright & Co., dated August 14, 2023, to $4,852,909 and filed a prospectus supplement (the
- $1.0 million — tock having an aggregate sales price of $1.0 million under the Offering Agreement. A copy of
Filing Documents
- tm2411778d3_8k.htm (8-K) — 29KB
- tm2411778d3_ex5-1.htm (EX-5.1) — 10KB
- tm2411778d3_ex5-1img001.jpg (GRAPHIC) — 10KB
- 0001104659-24-047368.txt ( ) — 269KB
- nrxp-20240415.xsd (EX-101.SCH) — 3KB
- nrxp-20240415_def.xml (EX-101.DEF) — 26KB
- nrxp-20240415_lab.xml (EX-101.LAB) — 36KB
- nrxp-20240415_pre.xml (EX-101.PRE) — 25KB
- tm2411778d3_8k_htm.xml (XML) — 5KB
01 Financial Statements
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Disclosure Law Group, a Professional Corporation 104 Cover Page Interactive Data File (embedded within Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: April 15, 2024 By: /s/ Stephen Willard Name: Stephen Willard Title: Chief Executive Officer